


<b>Name of Policy:</b>	<u>Pregnancy Screening Prior to Nuclear Medicine Therapeutic Procedures</u>	
<b>Policy Number:</b>	3364-135-163	
<b>Department:</b>	Radiology	
<b>Approving Officer:</b>	Chief Operating Officer - UTMC	
<b>Responsible Agent:</b>	Chairman & Professor, Radiology	
<b>Scope:</b>	Radiology	
		<b>Effective Date:</b> 12/1/2022
		Initial Effective Date: 11/14/2022
<input checked="" type="checkbox"/> New policy proposal <input type="checkbox"/> Minor/technical revision of existing policy		
<input type="checkbox"/> Major revision of existing policy <input type="checkbox"/> Reaffirmation of existing policy		

**(A) Policy Statement**

All female patients of childbearing age (typically 12-60 years old) who are undergoing therapeutic administrations of radioactive materials are required to submit to appropriate testing and restrictions to ensure that they are not pregnant at the time of dose administration, and will not become pregnant, until it is safe to do so.

Patients who are incapable of becoming pregnant (i.e., hysterectomy, menopause, etc.) are exempt from this policy, and any questions or clarifications regarding exemption must be discussed with the Authorized User prior to scheduling the procedure.

**(B) Purpose of Policy**

To prevent a radiopharmaceutical medical event and to eliminate the possibility of administering a therapeutic dose of radioactive material to an unborn child.



**(C) Procedure**

1. For all female patients:  
The intended patient will be required to submit a serum (blood) pregnancy test within twenty-four (24) hours of the intended administration, documenting a negative pregnancy status. Urine or dipstick pregnancy testing is not acceptable.
2. For all female patients receiving a therapeutic dose of sodium iodine I-131 in activities greater than thirty-three (33) mCi, or for administrations of a therapeutic dose of unsealed radioactive material other than I-131:

In addition to part 1, the intended patient must also attest and agree to abstinence of sexual intercourse a minimum of ten (10) calendar days prior to the date of administration of the radiopharmaceutical.

3. All patients will also be instructed to utilize effective contraception techniques to ensure that they will not become pregnant or impregnate another individual for at least one (1) year following treatment, or as discussed with the Authorized User.

4. This documentation will be reported and filed with the patient's radiation safety consultation and therapy consent paperwork.
5. Verification of pregnancy and breastfeeding status is the responsibility of the Nuclear Medicine Technologist and the Authorized User prior to radiopharmaceutical administration.
6. If it is determined that the patient is pregnant at the time of administration, or that the patient has failed to abstain from sexual intercourse for the ten-day period, the exam is to be aborted and/or rescheduled, and testing repeated at an appropriate date.

<b>Approved by:</b>  _____ Haitham Elsamaloty, MD Chairman & Professor, Radiology	<u>11/17/2022</u> Date	<b>Review/Revision Date:</b> 12/1/2022
 _____ Christine Stesney-Ridenour, FACHE Chief Operating Officer - UTMC	<u>11/22/2022</u> Date	
<b>Policies Superseded by This Policy</b>		<b>Next Review Date:</b> 12/1/2025